Zevra Therapeutics, Inc. Increase (Decrease) in Restricted Cash
Zevra Therapeutics, Inc. (ZVRA) reported Increase (Decrease) in Restricted Cash of $1.10 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2017-03-10
- Zevra Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2016-12-31 was $0.00.
- Zevra Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2016-09-30 was $0.00.
- Zevra Therapeutics, Inc. increase (decrease) in restricted cash for fiscal 2016 was $1.10M.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $0.00 derived: sum of 2 quarters · filed 2017-03-10 | $1.10M 10-K · filed 2017-03-10 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $1.10M 10-Q · filed 2016-11-10 | ||
| 2016-06-30 | $1.10M 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |